Five Prime Therapeutics, Inc. (NASDAQ:FPRX)‘s stock had its “buy” rating reaffirmed by analysts at Royal Bank Of Canada in a research report issued on Wednesday. They presently have a $41.00 target price on the biotechnology company’s stock. Royal Bank Of Canada’s price objective points to a potential downside of 5.70% from the stock’s current price.

A number of other analysts have also recently commented on the company. ValuEngine upgraded Five Prime Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st. BMO Capital Markets restated a “hold” rating and issued a $39.00 price objective on shares of Five Prime Therapeutics in a research report on Friday, September 22nd. Zacks Investment Research cut Five Prime Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, October 10th. BidaskClub cut Five Prime Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Wednesday, August 2nd. Finally, Jefferies Group LLC restated a “buy” rating and issued a $52.00 price objective on shares of Five Prime Therapeutics in a research report on Tuesday, September 12th. Two equities research analysts have rated the stock with a sell rating and nine have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $56.29.

Five Prime Therapeutics (NASDAQ FPRX) traded down 3.03% on Wednesday, reaching $43.48. The company’s stock had a trading volume of 400,538 shares. The company’s market capitalization is $1.22 billion. Five Prime Therapeutics has a 12-month low of $25.97 and a 12-month high of $60.98. The firm has a 50-day moving average of $39.15 and a 200 day moving average of $32.65.

Five Prime Therapeutics (NASDAQ:FPRX) last posted its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($1.58) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.15) by ($0.43). The business had revenue of $7.80 million during the quarter, compared to analysts’ expectations of $8.32 million. Five Prime Therapeutics had a negative net margin of 356.39% and a negative return on equity of 31.78%. The firm’s quarterly revenue was down 16.1% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.49) earnings per share. On average, equities research analysts anticipate that Five Prime Therapeutics will post ($5.29) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2017/10/25/five-prime-therapeutics-inc-fprx-earns-buy-rating-from-royal-bank-of-canada.html.

In other news, Director William R. Ringo sold 2,000 shares of Five Prime Therapeutics stock in a transaction that occurred on Thursday, September 28th. The stock was sold at an average price of $38.00, for a total value of $76,000.00. Following the sale, the director now directly owns 2,000 shares of the company’s stock, valued at $76,000. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director William R. Ringo sold 1,800 shares of Five Prime Therapeutics stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $40.26, for a total value of $72,468.00. Following the completion of the sale, the director now directly owns 1,200 shares in the company, valued at $48,312. The disclosure for this sale can be found here. Insiders own 6.50% of the company’s stock.

Several large investors have recently modified their holdings of FPRX. American International Group Inc. boosted its stake in shares of Five Prime Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 16,614 shares of the biotechnology company’s stock worth $601,000 after acquiring an additional 1,100 shares during the last quarter. Alliancebernstein L.P. boosted its stake in shares of Five Prime Therapeutics by 9.2% in the first quarter. Alliancebernstein L.P. now owns 97,770 shares of the biotechnology company’s stock worth $3,534,000 after acquiring an additional 8,220 shares during the last quarter. Teachers Advisors LLC boosted its stake in shares of Five Prime Therapeutics by 1.2% in the first quarter. Teachers Advisors LLC now owns 241,371 shares of the biotechnology company’s stock worth $8,726,000 after acquiring an additional 2,943 shares during the last quarter. Legal & General Group Plc boosted its stake in shares of Five Prime Therapeutics by 39.2% in the first quarter. Legal & General Group Plc now owns 9,168 shares of the biotechnology company’s stock worth $331,000 after acquiring an additional 2,583 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in shares of Five Prime Therapeutics by 11.0% in the first quarter. Dimensional Fund Advisors LP now owns 933,410 shares of the biotechnology company’s stock worth $33,743,000 after acquiring an additional 92,338 shares during the last quarter. 84.04% of the stock is currently owned by hedge funds and other institutional investors.

Five Prime Therapeutics Company Profile

Five Prime Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma.

Analyst Recommendations for Five Prime Therapeutics (NASDAQ:FPRX)

Receive News & Ratings for Five Prime Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.